NZ333064A - Subsituted dibenzofurans as inhibitors of matrix metalloproteinases - Google Patents

Subsituted dibenzofurans as inhibitors of matrix metalloproteinases

Info

Publication number
NZ333064A
NZ333064A NZ333064A NZ33306497A NZ333064A NZ 333064 A NZ333064 A NZ 333064A NZ 333064 A NZ333064 A NZ 333064A NZ 33306497 A NZ33306497 A NZ 33306497A NZ 333064 A NZ333064 A NZ 333064A
Authority
NZ
New Zealand
Prior art keywords
alkyl
matrix metalloproteinases
phenyl
formula
independently hydrogen
Prior art date
Application number
NZ333064A
Other languages
English (en)
Inventor
Joseph Armand Picard
Drago Robert Sliskovic
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NZ333064A publication Critical patent/NZ333064A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/76—Dibenzothiophenes

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Lubricants (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NZ333064A 1996-09-04 1997-09-02 Subsituted dibenzofurans as inhibitors of matrix metalloproteinases NZ333064A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2506396P 1996-09-04 1996-09-04
US5571497P 1997-08-07 1997-08-07
PCT/US1997/015444 WO1998009957A1 (en) 1996-09-04 1997-09-02 Compounds for and a method of inhibiting matrix metalloproteinases

Publications (1)

Publication Number Publication Date
NZ333064A true NZ333064A (en) 2000-11-24

Family

ID=26699217

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ333064A NZ333064A (en) 1996-09-04 1997-09-02 Subsituted dibenzofurans as inhibitors of matrix metalloproteinases

Country Status (10)

Country Link
US (1) US6294674B1 (cg-RX-API-DMAC10.html)
EP (1) EP0929542A1 (cg-RX-API-DMAC10.html)
JP (1) JP2002514180A (cg-RX-API-DMAC10.html)
KR (1) KR20000068415A (cg-RX-API-DMAC10.html)
AU (1) AU736347B2 (cg-RX-API-DMAC10.html)
BR (1) BR9712794A (cg-RX-API-DMAC10.html)
CA (1) CA2256631A1 (cg-RX-API-DMAC10.html)
HR (1) HRP970474B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ333064A (cg-RX-API-DMAC10.html)
WO (1) WO1998009957A1 (cg-RX-API-DMAC10.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6919375B1 (en) 1996-01-23 2005-07-19 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
NZ325939A (en) * 1996-01-23 2000-06-23 Shionogi & Co Sulphonated amino acid derivatives and matrix metalloproteinase inhibitors (MMP) containing these derivatives
MXPA99001974A (es) * 1996-12-09 2002-03-27 Warner Lambert Co Metodo para tratar y prevenir fallas cardiacas y dilatacion ventricular.
OA11589A (en) 1998-07-30 2004-07-30 Warner Lambert Co Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases.
US6350885B1 (en) 1998-07-30 2002-02-26 Warner-Lambert Company Tricyclic heteroaromatics and their derivatives as inhibitors of matrix metalloproteinases
WO2000015213A1 (en) * 1998-09-11 2000-03-23 Shionogi & Co., Ltd. Remedal or preventive agent for congestive heart failure
CN1229339C (zh) * 2000-03-27 2005-11-30 斯克里普斯研究学院 抑制血管生成和肿瘤生长的化合物,含有该化合物的药用制剂,以及该化合物的制药用途
GB2365425A (en) * 2000-08-01 2002-02-20 Parke Davis & Co Ltd Alkyl amino acid derivatives useful as pharmaceutical agents
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US20030129672A1 (en) * 2001-08-29 2003-07-10 Dyer Richard Dennis Method for identifying metalloenzyme inhibitors
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
CN1318411C (zh) * 2005-03-21 2007-05-30 中国海洋大学 氢化轮枝霉酮类化合物及其制备方法和用途
AU2006332694A1 (en) * 2005-12-30 2007-07-12 Alantos Pharmaceuticals, Holding, Inc. Substituted bis-amide metalloprotease inhibitors
EP2074107A2 (en) * 2006-10-27 2009-07-01 Wyeth a Corporation of the State of Delaware Tricyclic compounds as matrix metalloproteinase inhibitors
GB0621973D0 (en) * 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
AR066412A1 (es) * 2007-05-04 2009-08-19 Wyeth Corp Derivados de dibenzofurano y dibenzotiofeno, composiciones farmaceuticas que los contienen y usos en patologias tales como trastornos oseos, crecimiento de tumores, diabetes y obesidad.
CA2692004C (en) * 2007-06-15 2013-04-09 Board Of Regents, The University Of Texas System Methods and compositions to inhibit edema factor and adenylyl cyclase
JP2012051804A (ja) * 2008-12-26 2012-03-15 Kyoto Univ Eg5阻害剤
TWI747873B (zh) * 2016-02-01 2021-12-01 美商百歐克斯製藥公司 苯并吡唑化合物及其類似物
WO2021147882A1 (zh) * 2020-01-21 2021-07-29 深圳信立泰药业股份有限公司 一种二苯并呋喃类衍生物组织蛋白酶k抑制剂及其制备方法和医药用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2065966C3 (de) 1969-09-06 1978-11-16 Ajinomoto Co., Inc., Tokio N-Fluorenyl-sulfonyl-aminocarbonsäuren sowie diese enthaltende Mittel
US3845097A (en) 1969-09-06 1974-10-29 Ajinomoto Kk N-substituted amino acids and novel ester
US4097472A (en) 1974-11-08 1978-06-27 Mitsubishi Chemical Industries Limited N2 -arylsulfonyl-l-argininamides and the pharmaceutically acceptable salts thereof
DE2236876C3 (de) * 1971-08-19 1981-02-12 Ajinomoto Co., Inc., Tokio N-Substituierte Aminocarbonsäuren und diese Verbindungen enthaltende Arzneimittel
EP0183271B1 (en) * 1984-11-30 1990-05-16 Shosuke Okamoto Lysin derivative and proteinase inhibitor
PH31294A (en) * 1992-02-13 1998-07-06 Thomae Gmbh Dr K Benzimidazolyl derivatives, pharmaceutical compositions containing these compounds and process for preparing them.
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5627206A (en) 1995-06-02 1997-05-06 Warner-Lambert Company Tricyclic inhibitor of matrix metalloproteinases
US5665764A (en) 1995-06-02 1997-09-09 Warner-Lambert Company Tricyclic inhibitors of matrix metalloproteinases
DK0828726T3 (da) 1995-06-02 2002-01-21 Warner Lambert Co Tricykliske inhibitorer af matrixmetalloproteinaser
SK282833B6 (sk) 1995-11-17 2002-12-03 Warner-Lambert Company Sulfónamidové inhibítory matricových metaloproteináz a farmaceutická kompozícia obsahujúca tieto inhibítory
NZ325939A (en) 1996-01-23 2000-06-23 Shionogi & Co Sulphonated amino acid derivatives and matrix metalloproteinase inhibitors (MMP) containing these derivatives
NZ333063A (en) 1996-09-04 2000-12-22 Warner Lambert Co Dibenzofuran sulfonamide derivatives as matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
US6294674B1 (en) 2001-09-25
WO1998009957A1 (en) 1998-03-12
EP0929542A1 (en) 1999-07-21
KR20000068415A (ko) 2000-11-25
BR9712794A (pt) 1999-12-14
CA2256631A1 (en) 1998-03-12
JP2002514180A (ja) 2002-05-14
AU736347B2 (en) 2001-07-26
HRP970474A2 (en) 1998-12-31
HRP970474B1 (en) 2002-10-31
AU4177097A (en) 1998-03-26

Similar Documents

Publication Publication Date Title
HUP9902083A2 (hu) Mártix metalloproteináz gátló szulfonamidok
HU9601244D0 (en) Peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases
FI971412A0 (fi) Peptididyyliyhdisteet ja niiden terapeuttinen käyttö metalloproteaasien estäjinä
FI973087A0 (fi) Soluadheesion inhibiittoreita
DE69430816D1 (de) Verwendung von Piperidin-Derivaten in der Behandlung von Schizophrenie
ES2094350T3 (es) Cromano y tiocromanos con sustituyentes de feniletinilo en la posicion 7 que tienen actividad biologica de tipo retinoide.
ZA866940B (en) (n-substituted-2-hydroxy)benzamides and n-substituted-2-hydroxy-a-oxo-benzeneacetamides,pharmaceutical compositions and methods of use thereof having activity as modulators of the arachidonic acid cascade
NO843836L (no) Terapeutisk aktive sulfamatderivater
TR199801151T2 (xx) Trombin inhibit�r� �n ila�lar.
SE8804036L (sv) Ny anvaendning av 11,28-dioxa-4-azatricklo (22.3.1.04.9)-oktakos-18-en-derivat och farmaceutiska kompositioner innehaallande desamma
ES2037664T3 (es) Composiciones y metodos para el tratamiento de trastornos hemorragicos.
EP0604641A4 (en) COMPOSITION CONTAINING AMINO DERIVATIVES OR RELATED TO BENZOIC ACID AMINES AND USES THEREOF, INCLUDING IN THE TREATMENT OF INFLAMMATORY DISEASES.
NZ333063A (en) Dibenzofuran sulfonamide derivatives as matrix metalloproteinase inhibitors
BR9712794A (pt) Compostos para e um método de inibição de metaloproteinases matriciais
DE69619865D1 (de) Aromatische keto-säure und ihre derivate als inhibitoren der matrix metalloproteinase
TR200200410T2 (tr) Matris metaloproteinaz inhibitörleri olarak kullanışlı olan hidroksamik asit bileşikleri.
FI943850A0 (fi) 3-alkyylioksi-, aryylioksi- tai aryylialkyylioksibentso(b)tiofeeni-2-karboksamidit soluadheesion inhibiittoreina
MX9803901A (es) Compuestos de di-terbutilfenol que contienen azufre utiles como agentes anti-inflamatorios.
DK0828726T3 (da) Tricykliske inhibitorer af matrixmetalloproteinaser
ES8705382A1 (es) Un procedimiento para la preparacion de nuevos derivados de carbaciclina.
NZ332029A (en) Sulfonamide substituted chromans, process for their preparation, their use as a medicament and pharmaceutical preparations comprising them
DZ1959A1 (fr) Cyclohexane-1-ols 4,4-disubstitués monomères et composés apparentés.
MX9704740A (es) Monomeros de 3,3-(disustituido)ciclohexan-1-ol y compuestos relacionados.
IT1141071B (it) Impiego dell'alfa-chetoglutarato di piridossina nella terapia della iperlattacidemia

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)